Ascending Single Dose Study of the Safety, Tolerability, PK and PD of ATN-103 Administered SC or IV to Healthy Japanese Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 15 Jan 2013
At a glance
- Drugs Ozoralizumab (Primary) ; Ozoralizumab (Primary)
- Indications Psoriatic arthritis; Rheumatoid arthritis
- Focus Adverse reactions
- 14 Jan 2013 Drug company changed from Wyeth to Ablynx as reported by ClinicalTrials.gov.
- 21 Jun 2010 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
- 21 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.